Binimetinib is under clinical development by Pfizer and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Binimetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Binimetinib overview

Binimetinib (Mektovi) is a halobenzoic acid derivative, acts as anticancer agent. It is formulated as film coated tablets and coated tablets for oral route of administration. Mektovi is indicated for the treatment of  patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and BRAF mutant colorectal cancer.

Binimetinib (MEK-162, ARRY-162) is under development for the treatment of solid tumors including advanced, unresectable or metastatic cutaneous melanoma, metastatic thyroid cancer, triple-negative breast cancer, metastatic colorectal cancer, metastatic uveal melanoma, relapsed or refractory acute myeloid leukemia and acute lymphocytic leukemia, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma, chronic myelocytic leukemia, philadelphia positive acute leukemia, gastrointestinal stromal tumor, hepatocellular carcinoma, advanced non-small cell lung cancer, esophageal cancer and neurofibromatoses type I associated with plexiform neurofibroma. The drug candidate was also under development for the treatment of pancreatic ductal adenocarcinoma, metastatic biliary tract carcinoma, rheumatoid arthritis (RA), metastatic pancreatic adenocarcinoma, small-cell lung cancer, hypertropic cardiomyopathy, ovarian cancer, fallopian tube cancer, peritoneal cancer, melanoma, esophageal cancer, brain metastases, anaplastic pleomorphic xanthoastrocytoma, high grade glioma and metastatic uveal melanoma.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Binimetinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.